Crossmark

CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility

Crossref DOI link: https://doi.org/10.1038/ja.2016.89

Published Online: 2016-08-10

Published Print: 2017-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Krishnan, B Radha

James, Kenneth D

Polowy, Karen

Bryant, B J

Vaidya, Anu

Smith, Steve

Laudeman, Christopher P
License Information

Text and Data Mining valid from 2016-08-10
More Information

Article History

Received: 20 February 2016

Revised: 4 May 2016

Accepted: 17 May 2016

First Online: 10 August 2016

Competing interests

: KDJ, BRK and CPL have been consultants for and are stockholders of Cidara Therapeutics, the company developing CD101. AV is a stockholder of Cidara Therapeutics.